A placebo-controlled study for SPM 962 [rotigotine] in early parkinson's disease patients with non-concomitant treatment of L-dopa

Trial Profile

A placebo-controlled study for SPM 962 [rotigotine] in early parkinson's disease patients with non-concomitant treatment of L-dopa

Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 May 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 03 Jul 2012 Extension study details integrated (NCT01628965).
    • 03 Jul 2012 Extension study details integrated (NCT01628965).
    • 23 Jul 2010 Status changed from recruiting to completed according to presentation of results at the 14th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top